...INTERNSHIP REPORT INTERNSHIP REPORT T R E N D A N A L YS I S OF G E N E R I C S H I F T I NG I N T H E B A NG L A DE S H PHARMACEUTICAL MARKET (2006-2010) EMPLOYEE ORGANIZATION: SQUARE PHARMACEUTICALS LTD BANGLADESH PREPARED BY Monamee Afroze Ishika ID: 07104021 BRAC Business School BRAC University PREPARED FOR Mr. Anup Chowdhury Assistant Professor BRAC Business School BRAC University DATE of SUBMISSION 8th December, 2010 Transmittal Message December 08, 2010 Mr. Anup Chowdhury Assistant Professor, BRAC Business School BRAC University Subject: Submission of Internship Report Dear Sir, With great pleasure I am submitting my Internship report on Trend Analysis of Generic Shifting in the Bangladesh Pharmaceutical Market (2006-2010). I got the opportunity to work at country’s leading pharmaceutical company, world reputed Square Pharmaceuticals Limited (SPL) and was placed under one of the most important departments in the company Product Management Department (PMD). I have found the experience to be quite interesting and under the guidance of my supervisors and with the help of all the members of the department I have tried my level best to prepare an effective report on the above mentioned topic. The report contains the trend analysis of generic shifting, the reasons behind it and future potentiality of certain generic shifting events and SPL’s planning in the present scenario. Here I have gathered data and information through actual...
Words: 26333 - Pages: 106
...The context contemporary global business environment s requires companies to keep up with the pace of rapid changes and to meet financial expectations of numerous stakeholders. However these expectations are not financial only. Growing environmental concerns, depleting natural resources, globalisation issues, political and social instability require companies to reconsider their change management practices to comply with stakeholders expectations Pharmaceutical industry is no exception. The pharmaceutical industry has strategized around market exclusivity for many years. Successful commercialization of pharmaceutical products depends on maximizing the time available for product sales before generic products entered the market. Market protection opportunities that have the greatest impact on the life cycle of the product include patents, data exclusivity, patent term litigation, and extensions associated with pediatric indications for the drug (Goodman, 2008). Drug companies, their competitors which include other pharmaceutical companies, as well as generic companies understand this, thus enabling the drug companies to maximize product sales and royalties for many years (Goodman, 2008). These factors along with a declining economy, new healthcare regulations, political influences, changes in patent law, a change of the mentality from profits first, science secondary has lead to the decline in profits for the pharmaceutical industry. Although late adaptors to the “change”, unlike...
Words: 6651 - Pages: 27
...Corporate Development Strategies Faculty 02 – Economics and Business Administration Johann Wolfgang Goethe-University Frankfurt Industry analysis of the pharmaceutical industry Written assignment Submitted by: Heiko Kreuz, 4897736, s5706079@stud.uni-frankfurt.de Janine Seelinger, 4896818, s1010710@stud.uni-frankfurt.de Dana Winkler, 4497800, s1099437@stud.uni-frankfurt.de Supervisor: Prof. Dr. Lars Schweizer November 6, 2015 Table of contents 1 Introduction...........................................................................................................................1 2 Theoretical framework of Porter’s Five Forces ........................................................1 3 Industry analysis by means of Porter’s Five Forces ................................................2 3.1 Competitive rivalry ................................................................................................... 2 3.2 Bargaining power of suppliers.................................................................................. 2 3.3 Bargaining power of buyers ..................................................................................... 2 3.4 Threat of substitutes ................................................................................................. 3 3.5 Threat of new entrants .............................................................................................. 3 3.6 The regulators ............................
Words: 1934 - Pages: 8
...leading pharmaceutical company, world reputed Square Pharmaceuticals Limited (SPL). I was placed under one of the most important departments in the company Product Management Department (PMD). Basically PMD performs the all planning, implementation of plans as part of marketing management functions. My internship program instigated from 26, September, 2010 to 25, December, 2010 and during this period, I was assigned to do the project work on the topic Generic Shifting Analysis by my onsite supervisor. I was under the direct supervision of Mr. Dipak Kumar Saha, Senior Manager, PMD, Square Pharmaceuticals Limited and Mr. Anup Chowdhury, Assistant Professor, BRAC Business School, BRAC University for my internship program. Though the topic for my project work was assigned by my onsite supervisor but it was duly approve by my academic supervisor. The project is to investigate the trend toward which doctors‟ preference for any genric under any therapeutic class is shifting to another one. The report will definitely increase the knowledge of the department about the changing trend and preference of doctors regarding any generic which might help the department to plan their marketing effort considering these facts to make the plans more effective. 1.2OBJECTIVE The broad objective of this report is to explore the trend of generic shifting over a particular time period (2006-June, 2010). The main focus is to analyze the shifting in preference of molecule by the whole pharmaceutical industry...
Words: 23245 - Pages: 93
...Indian pharmaceutical industry is highly dynamic and offers great opportunities for both domestic and foreign companies. The industry is estimated to have generated revenue worth US$ 13.1 billion in FY 2011, according to a new Research and Market’s report, “Indian Pharma Sector Forecast 2014.” India will emerge as a leading global player in pharmaceutical industry by 2020, securing a place among the top five major global markets, according to Ikon Marketing Consultant (IMC). Also, Associated Chambers of Commerce and Industry (Assocham) has said it expects the Indian pharmaceutical industry to reach US$ 20 billion by 2015, making it one of the world's top 10 pharmaceuticals markets. India has a strong local manufacturing base and domestic players are developing substantial international presence. Healthcare is also one of the largest service sector industries in India, in terms of revenue and employment. Rising health awareness and increasing government expenditure on healthcare sector is driving growth in the sector. Medical tourism and health insurance are also on a rise, with significant growth in healthcare sector and establishment of large number of hospitals, both public and private. The Indian healthcare industry, estimated at US$ 50 billion, is expected to reach over US$ 75 billion by 2012, and US$ 100 billion by 2015. Talent Challenges While specialised talent is critical for any knowledge industry, it is more so within the pharmaceuticals industry. Companies gain competitive...
Words: 6445 - Pages: 26
...ur R&D clients include major pharmaceutical companies, medical device manufacturers, biotechs, and clinical research organizations. Our work, which spans all major therapeutic areas, focuses on: Driving innovation: We can help transform a company’s corporate culture and R&D infrastructure to meet changing industry needs, or support efforts to attract, motivate, and mobilize the best talent. We use our insights to help companies develop innovative products that offer substantial benefits over existing therapies, allowing them to overcome hurdles to regulatory approval and payor reimbursement. Improving productivity and performance: We have multiple strategies for enhancing client’s productivity and performance. For instance, we can help them access new technologies and innovation through various R&D financing and partnership models that minimize cost and risk. We also facilitate approval and reduce development timelines and costs by helping design clinical strategies that maximize the chance for a successful approval with the best possible label. Our efforts often involve assisting companies with organizational issues (e.g., helping them determine the most efficient structure post-merger, etc.). Since we understand the changing vendor landscape and we offer global reach and expertise, we can also assist companies in identifying the right outsourcing/off-shoring opportunities and in capturing greater value from emerging markets. Developing successful portfolio and asset strategies:...
Words: 843 - Pages: 4
...Introduction The world is a cold place these days for businesses seeking profitable international growth. In a few industries, firms have to be global if they are to achieve leadership. Implementing a global expansion strategy is crucial to the growth of a business from small start-up to international brand name. Companies such as McDonald's, Home Depot, Starbucks and more have made their presence known around the world over the past few decades. However, each global expansion presents its own set of obstacles which the parent company must tackle, in order to be successful in their global expansion. In a borderless world, companies need to compete on a global level in order to succeed. In today's world of financial uncertainty, it is important for businesses to have a clear idea of what stability involves for their company. One concept that more and more businesses are exploring is one of taking their business to a global level. Using an international strategy is not for every company, but with the availability of the Internet it is becoming easier to take your business to that next level. Global expansion may enable a firm to earn greater returns by transferring the product offerings derived from its core competencies to markets where indigenous competitors lack those product offerings and competencies. One of the global expansion strategies is merger and acquisition. Five waves of mergers and acquisitions took place in the 20th century, with the last two occurring in...
Words: 4340 - Pages: 18
...Strategy Formulation & Implementation Ranbaxy Laboratories Ltd 1. Summary: Indian pharmaceutical industry is estimated at $8 billion in 2013 and had been growing at an average rate of 8–9 %. The industry was highly fragmented with more than 1000 players out of which 30% of market was controlled by top ten companies and the rest of 70% by small companies. The Global pharmaceutical industry was estimated at $ 600 billion in 2013. Indian pharmaceutical industry has become more innovative and enterprising with more investment in R&D especially since the WTO agreement was signed. Indian drug makers command 10 per cent share in the USD 30 billion US generic drug market and also has the highest (over 150) US Foods & Drug Administration (FDA) approved facilities. US accounts for one-fourth of the Indian drug exports. The share of Indian pharma companies in the total approvals for generic drugs called Abbreviated New Drug Application (ANDA) has risen steadily. From 32 per cent in 2009, it went up to 38.5 per cent in 2013. Increasing share of Indian companies in total ANDAs approved by the USFDA can be attributed to increase spending by them for research and development (R&D) activities. As per CMIE’s database, the industry’s R&D expenses to sales ratio jumped to around five per cent in 2012-13 from around three per cent in 2003-04. The export of drugs from India is expected to grow by 4.2 per cent to USD 15.2 billion in 2013-14. Around USD 16.3 billion of drugs are likely to be...
Words: 11886 - Pages: 48
...has today burgeoned into one of the top line conglomerates in Bangladesh. Square Pharmaceuticals Ltd., the flagship company, is holding the strong leadership position in the pharmaceutical industry of Bangladesh since 1985 and is now on its way to becoming a high performance global player. SQUARE today is more than just an organization, it is an institute. In a career spanning across four and half decades it has pioneered the development of the local business in fields as diverse as Pharmaceuticals, Toiletries, Garments, Textile, Information Technology, Health Products, Food Products, Hospital, etc. With an average Annual turnover of over US$ 200 million and a workforce of about 3500 the SQUARE Group is a true icon of the Bangladesh business sector. Vision satement We view business as a means to the material and social wellbeing of the investors, employees and the society at large, leading to accretion of wealth through financial and moral gains as a part of the process of the human civilization. Mission statement Our Mission is to produce and provide quality & innovative healthcare relief for people, maintain stringently ethical standard in business operation also ensuring benefit to the shareholders, stakeholders and the society at large. Chapter B: Company Profile History of Square Group 1958 : | Debut of Square Pharma as a Partnership Firm. | 1964 : | Converted into a Private Limited Company. | 1974 : | Technical Collaboration...
Words: 5298 - Pages: 22
...Pharmaceutical Sector of Bangladesh The pharmaceutical industry in Bangladesh is one of the most developed technology sectors within Bangladesh. Manufacturers produce insulin, hormones, and cancer drugs. This sector provides 97% of the total medicinal requirement of the local market. The industry also exports medicines to global markets, including Europe. Pharmaceutical companies are expanding their business with the aim to expand the export market. History Right after liberation war three fourth of the pharmaceutical industries was dominated by multinational companies. The National Drug Policy (NDP) in 1982 and 2005 has major impact in the development and growth of the Bangladesh pharmaceutical industry. Key points of National Drug Policy of 1982 To provide administrative and legislative support for ensuring quality of essential drugs which are relevant to the national health need. To reduce the price of medicine by ensuring the lowest competitive price. To eliminate non-essential medicine from the market To promote production of local drug and raw materials. To develop proper drug monitoring and information system to prevent wasteful misuse and to ensure the proper utilization of the drugs. To ensure GMP and qualified pharmacist in manufacturing companies. Drug Regulatory Authorities in Bangladesh • The Directorate General of Drug Administration (DGDA) • The Pharmacy Council of Bangladesh (PCB) Local Market Overview The Bangladesh...
Words: 998 - Pages: 4
...Pharmaceutical industry The pharmaceutical industry develops, produces, and markets drugs licensed for use as medications.[1] Pharmaceutical companies are allowed to deal in generic and/or brand medications and medical devices. They are subject to a variety of laws and regulations regarding the patenting, testing and ensuring safety and efficacy and marketing of drugs. Indian Pharmaceutical Industry The pharmaceutical industry in India is among the most highly organized sectors. This industry plays an important role in promoting and sustaining development in the field of global medicine. Due to the presence of low cost manufacturing facilities, educated and skilled manpower and cheap labor force among others, the industry is set to scale new heights in the fields of production, development, manufacturing and research. In 2008, the domestic pharma market in India was expected to be US$ 10.76 billion and this is likely to increase at a compound annual growth rate of 9.9 per cent until 2010 and subsequently at 9.5 per cent till the year 2015. | Industry Trends : * The pharma industry generally grows at about 1.5-1.6 times the Gross Domestic Product growth * Globally, India ranks third in terms of manufacturing pharma products by volume * The Indian pharmaceutical industry is expected to grow at a rate of 9.9 % till 2010 and after that 9.5 % till 2015 * In 2007-08, India exported drugs worth US$7.2 billion in to the US and Europe followed by Central and Eastern...
Words: 2809 - Pages: 12
...sector overview and Major players The Indian Pharmaceutical industry is highly fragmented with about 24,000 players (around 330 in the organised sector). The top ten companies make up for more than a third of the market. The Indian pharma industry (IPM) grew by 16% YoY in 2012 to ` 629 bn. It accounts for about 1.4% of the world's pharma industry in value terms and 10% in volume terms. Besides the domestic market, Indian pharma companies also have a large chunk of their revenues coming from exports. While some are focusing on the generics market in the US, Europe and semi-regulated markets, others are focusing on custom manufacturing for innovator companies. Biopharmaceuticals is also increasingly becoming an area of interest given the complexity in manufacture and limited competition. The drug price control order (DPCO) continues to be a menace for the industry. There are three tiers of regulations – on bulk drugs, on formulations and on overall profitability. This has made the profitability of the sector susceptible to the whims and fancies of the pricing authority. In connotation, with pricing policy of 354 drugs, NLEM (National list of essential medicines) was released, which covered the list of the drugs which the authority intends to put under price control. The policy has been stiffly opposed by the pharmaceutical industry. Introduction of GDUFA (Generic drug user fee Act) in US. As per this act, the generic companies are required to pay user fees to USFDA, for application...
Words: 1721 - Pages: 7
...Laboratories Ltd (DRL), a global pharmaceutical company. Established in 1984, DRL was the largest Indian pharmaceutical company with a net worth of Rs.58 billion in 2007. As a fully integrated pharmaceutical company, DRL provided affordable medicines through its three core businesses - Pharmaceutical Services and Active Ingredients, Global Generics, and Proprietary Products. Since 2008, however, the drug maker went through a very difficult phase. The acquisition of German generics company betapharm Arzneimittel GmbH (Betapharm) in 2006 backfired, sinking the company into its worst ever quarterly loss in the fiscal 2008-09. Pending lawsuits for alleged patent infringements prevented DRL from launching generic products in its biggest market, the US. Moreover the ban imposed by the US Food and Drug Administration (FDA) on products made at DRL's Mexico unit for violation of manufacturing practices seriously dented the company's image as a quality drug maker. The ban also affected the company's revenues from the US market. A string of accidents which broke out across at DRL's Indian manufacturing facilities brought its safety practices under question. In a bid to crack the generics market in the US, the company lost sight of the domestic market and could not come up with new products in the Indian markets unlike its competitors. As a result, the company lost its coveted position in the domestic market. All these problems led to a decline in the stock price of the company. It was also reported...
Words: 1901 - Pages: 8
...ORGANIZATIONAL DESIGN OF SQUARE PHARMACEUTICALS LTD. BASED ON 2006 - 2007 COMPANY ACTIVITIES April 20, 2008 ORGANIZATIONAL DESIGN OF SQUARE PHARMACEUTICALS LTD. BASED ON 2006 - 2007 COMPANY ACTIVITIES April 20, 2008 Members of the Group Acknowledgment A single individual can achieve no noble objective. We are indebted to a number of persons for their kind advice, suggestions, directions, & co-operations which have enable us to prepare this report. First of all I would like to thank Utpual for his contribution into this report. We would like to thank Kazal Pharmacy for their suggestion and ideas. Riaheen Farzana Senior Lecturer ULAB School of Business University of Liberal Arts Bangladesh Dhanmondi, Road- 4/A Satmosjid Road, Dhaka-1209 Subject: Submission...
Words: 4202 - Pages: 17
...The Lawyers & Jurists Career Upload Works Monthly Journals Set Up Business Home About Us Our Lawyers Our Clients Services Career Online resources Contact Us Here you are: The Lawyers & Jurists > resources > Industries > Supply Chain Management SYSTEMS of SQUARE PHARMACEUTICALS LTD. Supply Chain Management SYSTEMS of SQUARE PHARMACEUTICALS LTD. view with images and charts Supply Chain Management SYSTEMS of SQUARE PHARMACEUTICALS LTD. Introduction: Formally designed Commercial Department has been renamed as “Supply Chain Management” (SCM) in Mid July 2007. When only one Manager was guiding as Head of the Department but there was no gap for monitoring the officers’ activities. SCM started its journey with wider functions as a result it would divide into two folds – Local Purchase International Trade Manager for the new section take responsibility to supervise activities more effectively and efficiently. Number of potential individuals have joined in SCM who are doing there jobs with total satisfaction. DGM is guiding works of both the sections and Executive Director (Admin) is monitoring & advising overall activities monitoring. SCM has recently generated new SOP considering present work volume and business environment. And DGM is getting to the point all out support and cooperation of Manager – International Trade and Manager – Local Purchase. Presently about 42 people are working in SCM. SCM...
Words: 8546 - Pages: 35
